Nocturnal enuresis is involuntary voiding that occurs exclusively at night, after most children have stopped. For the diagnosis of primary monosymptomatic enuresis, at least three episodes of bed wetting in a patient who has never been dry for more than six months are required (PME). Despite a 15 % annual maturation rate, 0.5 % of all instances continue throughout adulthood, with significant effects for self-esteem. Behavioral and motivational therapy, alarm aids, and pharmacotherapy have all been recommended as therapeutic options for PME. Desmopressin or antimuscarinics like propiverine or oxybutynin are the most common medical treatments for PME. Response failure to these medications is one of the issues in the management of PME. In recent literature, the influence of medicines that modulate serotonin levels, such as selective serotonin reuptake inhibitors (SSRIs), on urination has been reported. These findings show that SSRIs might be used to treat nocturnal enuresis without the dangerous cardiac arrhythmia that tricyclic antidepressants cause or the hyponatremia that long-term desmopressin therapy causes. The goal of our research was to look at the role of fluoxetine in the treatment of enuresis in children.